Clay Rowland joined the T1D fund in January 2022. Prior to joining the Fund, Clay worked in corporate development at Syros Pharmaceuticals, a clinical stage biotech developing small molecules to treat cancer and rare genetic diseases. At Syros, Clay helped develop and execute the company’s business development strategy and was involved across all stages of both in-licensing and out-licensing transactions, which included in-licensing the company’s third clinical stage asset and executing a global clinical collaboration with Roche.
Prior to this, Clay worked as a Consultant at Artisan Healthcare Consulting, working with large pharmaceutical and biotech clients on corporate strategy, new product planning, business development, and portfolio prioritization projects. He received his B.A. in Biology from Colby College and minored in Economics.